Related Experiment Video

Updated: Jun 21, 2026

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages
08:26

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Published on: February 23, 2024

The future of targeted therapies in ovarian cancer

Susana Banerjee1, Martin Gore

  • 1The Royal Marsden Hospital, London, SW3 6JJ, United Kingdom.

The Oncologist
|July 14, 2009
PubMed

Insights

Targeted therapies offer new hope for ovarian cancer, a leading cause of gynecological cancer death. Research is exploring novel agents like antiangiogenic drugs and PARP inhibitors to overcome treatment resistance and improve patient outcomes.

Area of Science:

  • Gynecologic Oncology
  • Cancer Therapeutics
  • Molecular Biology

Background:

  • Ovarian cancer is a leading cause of gynecological cancer mortality.
  • Advanced stage at diagnosis limits curative potential.
  • Current treatments show limited efficacy and high recurrence rates.

Purpose of the Study:

  • To review emerging targeted therapeutic approaches for ovarian cancer.
  • To discuss the clinical investigation of novel agents.
  • To identify challenges in the clinical application of these therapies.

Main Methods:

  • Review of clinical investigations and preclinical studies.
  • Focus on molecularly directed therapies.
  • Analysis of antiangiogenic agents and poly (ADP-ribose) polymerase (PARP) inhibitors.

Main Results:

  • Targeted therapies aim to block specific molecular pathways in cancer cells and the tumor microenvironment.
  • Antiangiogenic agents and PARP inhibitors show promise.
  • Several targeted agents are under active clinical investigation.

Conclusions:

  • Targeted therapies represent a promising strategy to improve ovarian cancer treatment outcomes.
  • Overcoming therapeutic resistance remains a critical challenge.
  • Further research and clinical trials are essential for successful implementation.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...